(6R,7R)-3-[1-(carboxymethyl)tetrazol-5-ylsulfanylmethyl]-7-methoxy-7-(2-methoxybenzamido)-1-oxa-3-cephem-4-carboxylic acid 3-methylbenzyl ester

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (6R,7R)-3-[1-(carboxymethyl)tetrazol-5-ylsulfanylmethyl]-7-methoxy-7-(2-methoxybenzamido)-1-oxa-3-cephem-4-carboxylic acid 3-methylbenzyl ester
• 英文别名: (6R,7R)-3-(1-Carboxymethyl-1H-tetrazol-5-ylsulfanylmethyl)-7-methoxy-7-(2-methoxy-benzoylamino)-8-oxo-5-oxa-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid 3-methyl-benzyl ester；2-[5-[[(6R,7R)-7-methoxy-7-[(2-methoxybenzoyl)amino]-2-[(3-methylphenyl)methoxycarbonyl]-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-en-3-yl]methylsulfanyl]tetrazol-1-yl]acetic acid
• 化学式: C₂₈H₂₈N₆O₉S
• 分子量: 624.631
• InChiKey: WWSPYUUDJNNJFH-IAPPQJPRSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.3
• 重原子数：
  44
• 可旋转键数：
  13
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.32
• 拓扑面积：
  210
• 氢给体数：
  2
• 氢受体数：
  13

反应信息

• 作为产物：
  描述：

  3-甲基苄溴 在 氯 、 碳酸氢钠 、 magnesium 、 溶剂黄146 、 三乙胺 、 sodium 2-ethylhexanoic acid 作用下， 以 甲醇 、 四氯化碳 、 二氯甲烷 、 乙酸乙酯 、 乙腈 为溶剂， 生成 (6R,7R)-3-[1-(carboxymethyl)tetrazol-5-ylsulfanylmethyl]-7-methoxy-7-(2-methoxybenzamido)-1-oxa-3-cephem-4-carboxylic acid 3-methylbenzyl ester
  参考文献：
  名称：

  新型的基于1-氧杂酚的人类糜酶抑制剂的合成与构效关系。

  摘要：

  合成了1-Oxacephem衍生物，并将其评估为一系列新型的糜酶抑制剂。1-氧嘧啶的构效关系研究导致了化合物34，与其他丝氨酸酶相比，该化合物对人糜酶的抑制作用为6 nM，对人糜酶的选择性较高。

  DOI：

  10.1016/s0960-894x(00)00488-1

文献信息

• DRUG CONTAINING CHYMASE INHIBITOR AS THE ACTIVE INGREDIENT
  申请人：Teijin Pharma Limited

  公开号：EP1666067A1

  公开（公告）日：2006-06-07

  The present invention provides drugs containing chymase inhibitors as active ingredients for improving glucose intolerance or preventing and/or treating diseases caused by glucose intolerance. The diseases caused by glucose intolerance are diabetes and/or diabetes complications, wherein the diabetes complications include diabetic nephropathy, diabetic retinopathy, diabetic peripheral neuropathy, hyperinsulinism, insulin resistance syndrome, arteriosclerosis, acute coronary syndrome, arteriosclerosis obliterans, angitis, stroke, hypertension, renal insufficiency, nephropathy, nephritis, renal artery aneurysm, renal infarction, obesity and the like.

  本发明提供了含有糜蛋白酶抑制剂作为活性成分的药物，用于改善葡萄糖不耐受症或预防和/或治疗葡萄糖不耐受症引起的疾病。葡萄糖不耐受引起的疾病是糖尿病和/或糖尿病并发症，其中糖尿病并发症包括糖尿病肾病、糖尿病视网膜病变、糖尿病周围神经病变、高胰岛素血症、胰岛素抵抗综合征、动脉硬化、急性冠脉综合征、动脉硬化闭塞症、血管炎、中风、高血压、肾功能不全、肾病、肾炎、肾动脉瘤、肾梗塞、肥胖症等。
• Drug containing chymase inhibitor as the active ingredient
  申请人：Urata Hidenori

  公开号：US20070032466A1

  公开（公告）日：2007-02-08

  The present invention provides drugs containing chymase inhibitors as active ingredients for improving glucose intolerance or preventing and/or treating diseases caused by glucose intolerance. The diseases caused by glucose intolerance are diabetes and/or diabetes complications, wherein the diabetes complications include diabetic nephropathy, diabetic retinopathy, diabetic peripheral neuropathy, hyperinsulinism, insulin resistance syndrome, arteriosclerosis, acute coronary syndrome, arteriosclerosis obliterans, angitis, stroke, hypertension, renal insufficiency, nephropathy, nephritis, renal artery aneurysm, renal infarction, obesity and the like.
• Synthesis and structure–activity relationships of a new class of 1-oxacephem-based human chymase inhibitors
  作者：Yasunori Aoyama、Masaaki Uenaka、Toshiro Konoike、Yasuyoshi Iso、Yasuhiro Nishitani、Akiko Kanda、Noriyuki Naya、Masatoshi Nakajima

  DOI：10.1016/s0960-894x(00)00488-1

  日期：2000.11

  1-Oxacephem derivatives were synthesized and evaluated as a novel series of chymase inhibitors. Structure-activity relationship studies of 1-oxacephems led to compound 34, which exhibited 6 nM inhibition of human chymase and high selectivity for human chymase compared to other serine enzymes.

  合成了1-Oxacephem衍生物，并将其评估为一系列新型的糜酶抑制剂。1-氧嘧啶的构效关系研究导致了化合物34，与其他丝氨酸酶相比，该化合物对人糜酶的抑制作用为6 nM，对人糜酶的选择性较高。